A detailed history of Woodline Partners LP transactions in Kal Vista Pharmaceuticals, Inc. stock. As of the latest transaction made, Woodline Partners LP holds 608,253 shares of KALV stock, worth $5.45 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
608,253
Previous 150,462 304.26%
Holding current value
$5.45 Million
Previous $1.77 Million 297.46%
% of portfolio
0.06%
Previous 0.02%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$9.46 - $15.39 $4.33 Million - $7.05 Million
457,791 Added 304.26%
608,253 $7.04 Million
Q1 2024

May 15, 2024

SELL
$11.07 - $16.04 $2.17 Million - $3.15 Million
-196,401 Reduced 56.62%
150,462 $1.78 Million
Q4 2023

Feb 14, 2024

BUY
$7.58 - $12.25 $2.63 Million - $4.25 Million
346,863 New
346,863 $4.25 Million
Q2 2023

Aug 14, 2023

BUY
$7.73 - $10.57 $837,607 - $1.15 Million
108,358 New
108,358 $975,000
Q4 2022

Feb 14, 2023

SELL
$4.2 - $14.24 $668,098 - $2.27 Million
-159,071 Reduced 21.13%
593,810 $4.01 Million
Q3 2022

Nov 14, 2022

SELL
$9.85 - $16.83 $3.29 Million - $5.62 Million
-334,002 Reduced 30.73%
752,881 $10.9 Million
Q2 2022

Aug 15, 2022

BUY
$8.16 - $15.1 $4.81 Million - $8.91 Million
589,869 Added 118.68%
1,086,883 $10.7 Million
Q1 2022

May 16, 2022

BUY
$11.2 - $16.97 $4.01 Million - $6.08 Million
358,276 Added 258.24%
497,014 $7.33 Million
Q4 2021

Feb 14, 2022

BUY
$12.36 - $18.28 $116,023 - $171,594
9,387 Added 7.26%
138,738 $1.84 Million
Q3 2021

Nov 15, 2021

BUY
$17.11 - $24.49 $473,005 - $677,026
27,645 Added 27.18%
129,351 $2.26 Million
Q2 2021

Aug 16, 2021

SELL
$23.12 - $29.91 $2.83 Million - $3.66 Million
-122,353 Reduced 54.61%
101,706 $2.44 Million
Q1 2021

May 17, 2021

BUY
$14.69 - $42.57 $3.29 Million - $9.54 Million
224,059 New
224,059 $5.76 Million

Others Institutions Holding KALV

About KalVista Pharmaceuticals, Inc.


  • Ticker KALV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 24,602,000
  • Market Cap $220M
  • Description
  • KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...
More about KALV
Track This Portfolio

Track Woodline Partners LP Portfolio

Follow Woodline Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Woodline Partners LP with notifications on news.